Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Post by shareswapperon Dec 30, 2020 1:27pm
176 Views
Post# 32198329

Interesting CEO Comments!!

Interesting CEO Comments!!He talked about "Strategic Alternatives" that they have been working on and the fact that he is confident they will "bear fruit" in 2021.  Also spoke to Oral Amp B and partnering activities but did not elaborate other than to say they are progressing.  He thanked Shareholders for patience in 2020 in trying times.  One shareholder expressed his concern about IR and was assured a call back by the CEO.  Nothing material disclosed as expected, but very obvious they are active as a Managemnt Team and working diligently behind the scenes.  Patience required here .....  I'm satisfied this is a Stock to hold and even accumulate based on the potential of the Assets and the value gap here.  Good Luck to Shareholders in 2021!!!
<< Previous
Bullboard Posts
Next >>